Navigation Links
DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Date:8/19/2007

SAN DIEGO and AUSTIN, Texas, Aug. 16 /PRNewswire/ -- DJO Incorporated (NYSE: DJO), a global provider of products and services that promote musculoskeletal and vascular health, today reported that on August 9, 2007, the U.S. Federal Trade Commission ("FTC") granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for the proposed acquisition of DJO by an affiliate of ReAble Therapeutics, Inc. ("ReAble").

On July 16, 2007, DJO announced that it had entered into an agreement and plan of merger under which an affiliate of ReAble will acquire all outstanding shares of DJO's common stock for a cash payment of $50.25 per share. An affiliate of The Blackstone Group ("Blackstone") is the controlling shareholder of ReAble. On July 27, 2007, DJO and Blackstone submitted pre-merger notification and report forms with the FTC and the United States Department of Justice, Antitrust Division. The granting of early termination of the waiting period means the proposed acquisition has cleared U.S. antitrust review, but remains subject to satisfaction of several other conditions, including approval of the transaction by DJO's stockholders and the expiration or termination of the waiting period under the German Act Against Restraints of Competition.

Additional Information and Where to Find It

In connection with the proposed transaction, DJO intends to file a proxy statement with the Securities and Exchange Commission (the "SEC"). STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT (AND ALL AMENDMENTS AND SUPPLEMENTS TO IT) AND OTHER MATERIALS THAT THE COMPANY MAY FILE WITH THE SEC IN THEIR ENTIRETY WHEN SUCH MATERIALS BECOME AVAILABLE, BECAUSE THE MATERIALS
'/>"/>

SOURCE ReAble Therapeutics Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Doyle urges support of higher education spending
2. Doyle outlines spending for Medical College, UWM
3. Chippewa Valley to get $46 million in defense spending
4. In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde
5. Audit of multi-million dollar state IT spending will proceed
6. Stratagene sets aside $21M to pay Third Wave pending appeal
7. New report says Wisconsin R&D spending exceeding expectations
8. IT Spending to Increase in Second Half of 2003
9. Technology and mergers: Getting the strategic applications
10. AT&T - BellSouth merger: Revestiture continues
11. CDW names VP to handle Berbee merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 02, 2015 Sterlitech is proud ... testing system at the 2015 AMTA Membrane Technology Conference ... of a decade’s worth of engineering and customer feedback, ... a wide range of applications across an array of ... to meet the dynamic needs of researchers and engineers ...
(Date:3/1/2015)... London, UK (PRWEB) March 01, 2015 ... a partnership agreement for quality market research promotion ... and sell research reports worked out by DataGroup ... Department at Market Publishers Ltd, commented on the ... to have DataGroup Booksellers in our team of ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, ... XON ), a leader in synthetic biology, today announced ... Specialty Fruits (OSF), the pioneering agricultural company behind ... first non-browning apple. Through the acquisition, Intrexon expands its ... more appetizing and convenient for consumers while providing economic ...
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Global Market Report of Trypsin 2014-2018 2
... Switzerland and PARIS, October 13 Debiopharm,Group ... companies,with a focus on the development of ... Ipsen (Euronext: FR0010259150; IPN), an innovation-driven,global specialty ... of Decapeptyl(R)[1] (triptorelin embonate[2],22.5 mg) successfully completed ...
... 12 Epeius Biotechnologies Corporation today announced more stunning ... world,s first and, so far only, tumor-targeted genetic medicine ... therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has ... much-touted biologics have failed to do: that is, to ...
... study presented at the 49th Interscience Conference on Antimicrobial ... UV device to decontaminate hospital rooms at the Cleveland ... its ability to remove troublesome bacteria, including C. difficile ... germicidal energy to decontaminate air and surfaces, including those ...
Cached Biology Technology:Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 2Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 3Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 4Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 5Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer 6Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 2Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine 3Researchers Present 'a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination' 2Researchers Present 'a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination' 3
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... 2009 -- With each passing year, the human population of ... wide ranging strain on our water and soil resources, as ... the issue of food security. One way that scientists are ... seeds, both as a method of improving crop yields as ...
... Gene therapy , Gene therapy is the introduction of genetic ... a therapeutic effect. In recent years, it has been ... or even cure several fatal diseases for which there is ... for hereditary diseases, but also for other diseases that affect ...
... in safe and effective administration of potential antiviral drugs ... first step in development of a new kind of treatment ... 4 as an advance online publication of Nature Materials ... and treatment of human disease," said lead author Kim ...
Cached Biology News:Food security: It starts with seed 2Moving gene therapy forward with mobile DNA 2Nanotechnology holds promise for STD drug delivery 2